AGMB 101
Alternative Names: AGMB-101; ARGX-114Latest Information Update: 03 Jan 2023
At a glance
- Originator AgomAb Therapeutics
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Fibrosis; Inflammation; Liver failure; Soft tissue injuries
Most Recent Events
- 04 Nov 2022 The pharmacodynamics data from preclinical studies in acute liver failure presented at the American Association for the Study of Liver Diseases (AASLD-2022)
- 03 Nov 2022 Preclinical trials in Liver failure in Belgium (Parenteral) before November 2022
- 13 Jul 2022 Preclinical trials in Soft tissue injuries in Belgium (Parenteral)